Effects of intensive glucose lowering in type 2 diabetes.

PubWeight™: 47.90‹?› | Rank: Top 0.01% | All-Time Top 1000

🔗 View Article (PMC 4551392)

Published in N Engl J Med on June 06, 2008

Authors

Action to Control Cardiovascular Risk in Diabetes Study Group, Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm, Jeffrey L Probstfield, Denise G Simons-Morton, William T Friedewald

Associated clinical trials:

Action to Control Cardiovascular Risk in Diabetes (ACCORD) (ACCORD) | NCT00000620

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (FLAT-SUGAR) | NCT01524705

HbA1c Variability in Type II Diabetes | NCT02879409

Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE) (RCT-IVVE) | NCT02762851

Dietary Intervention in Type-2 Diabetes and Pre-Diabetes | NCT02519309

Influenza Vaccine To Prevent Adverse Vascular Events:Pilot (IVVE:Pilot) | NCT01945268

Carotid Atherosclerosis In Newly Diagnosed Type 2 Individuals (DIABIMCAP) | NCT01898572

Pilot Study of Glycemic Control in Diabetic Hemodialyzed Patients (GlyCEDIA) | NCT01828970

A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation | NCT01123122

Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification | NCT03196895

Benefits of Continuous Glucose Monitoring With GEM Lifestyle Modification for Adults With Type 2 Diabetes | NCT03207893

Changes in the Retinal and Carotid Microcirculation After Restoring Normoglycemia in Patients With Type 2 Diabetes (OCTAUS-T2D) | NCT03594591

Effect of Postprandial Hyperglycemia on Vasculature in DM1 and Healthy Adults (WBH001) | NCT04730882

Articles citing this

(truncated to the top 100)

Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85

National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet (2011) 24.73

Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28

Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62

Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05

Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66

Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40

Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78

Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med (2010) 13.25

A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15

The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med (2009) 12.13

Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20

Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14

Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA (2009) 7.78

Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med (2011) 7.42

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ (2010) 6.11

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ (2011) 5.77

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care (2008) 5.43

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med (2011) 4.76

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care (2010) 4.67

The barrier of hypoglycemia in diabetes. Diabetes (2008) 4.50

Cluster-randomized trial of a mobile phone personalized behavioral intervention for blood glucose control. Diabetes Care (2011) 4.38

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 4.33

Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med (2009) 4.31

Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol (2014) 4.30

Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA (2014) 4.23

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med (2012) 4.02

Investigating the relationship between quality of primary care and premature mortality in England: a spatial whole-population study. BMJ (2015) 4.02

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care (2013) 3.89

Diabetes in older adults: a consensus report. J Am Geriatr Soc (2012) 3.63

Diabetes in older adults. Diabetes Care (2012) 3.62

Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet (2014) 3.53

Recommendations on screening for type 2 diabetes in adults. CMAJ (2012) 3.51

Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48

Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study. J Pediatr (2009) 3.48

Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA (2015) 3.33

Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care (2009) 3.30

The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ (2010) 3.26

Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol (2011) 3.25

Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med (2013) 3.25

Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care (2012) 3.24

Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation (2009) 3.23

Fetuses of obese mothers develop insulin resistance in utero. Diabetes Care (2009) 3.05

American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97

Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes (2009) 2.96

Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care (2013) 2.96

A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus: 5 year results of the IDEATel study. J Am Med Inform Assoc (2009) 2.90

Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes (2015) 2.87

Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med (2008) 2.79

Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care (2011) 2.75

The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev (2008) 2.73

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet (2013) 2.66

National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med (2014) 2.61

Insulin resistance is a cellular antioxidant defense mechanism. Proc Natl Acad Sci U S A (2009) 2.60

Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care (2011) 2.54

Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care (2009) 2.50

Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ (2011) 2.49

National trends in treatment of type 2 diabetes mellitus, 1994-2007. Arch Intern Med (2008) 2.43

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care (2012) 2.43

Cardiovascular biology of the incretin system. Endocr Rev (2012) 2.42

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ (2009) 2.42

Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.42

Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract (2009) 2.40

Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes (2009) 2.34

Peer mentoring and financial incentives to improve glucose control in African American veterans: a randomized trial. Ann Intern Med (2012) 2.32

Active care management supported by home telemonitoring in veterans with type 2 diabetes: the DiaTel randomized controlled trial. Diabetes Care (2009) 2.31

Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med (2014) 2.25

Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24

Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int (2014) 2.22

Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care (2014) 2.20

Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord (2010) 2.19

Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med (2014) 2.17

Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol (2014) 2.16

Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.15

Managing medications in clinically complex elders: "There's got to be a happy medium". JAMA (2010) 2.14

Impact of electronic health record clinical decision support on diabetes care: a randomized trial. Ann Fam Med (2011) 2.11

2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J (2016) 2.09

Heart failure: epidemiology and prevention in India. Natl Med J India (2011) 2.09

Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol (2009) 2.08

Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care (2011) 2.04

Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes (2008) 2.04

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J (2013) 2.02

Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol (2009) 2.01

Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care (2009) 2.00

American Geriatrics Society identifies five things that healthcare providers and patients should question. J Am Geriatr Soc (2013) 1.99

The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One (2013) 1.95

Independent but coordinated trials: insights from the practice-based Opportunities for Weight Reduction Trials Collaborative Research Group. Clin Trials (2010) 1.93

The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care (2015) 1.93

Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol (2011) 1.92

Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int (2011) 1.91

Night time blood pressure variability is a strong predictor for cardiovascular events in patients with type 2 diabetes. Am J Hypertens (2008) 1.91

Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Intern Med (2014) 1.91

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care (2009) 1.89

The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology (2014) 1.89

Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc (2009) 1.88

Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation (2011) 1.88

Articles cited by this

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 95.79

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06

Standards of medical care in diabetes--2008. Diabetes Care (2008) 17.23

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med (2004) 10.35

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J (2007) 9.80

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62

American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract (2007) 7.55

Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet (2006) 6.64

Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78

A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes (1970) 4.57

The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia (2005) 4.45

Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21

Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.14

Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.49

Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med (1997) 3.35

Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia (2001) 3.33

Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications (2003) 3.33

Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 3.17

Trends in the mortality burden associated with diabetes mellitus: a population-based study in Rochester, Minn, 1970-1994. Arch Intern Med (2003) 3.13

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J (2007) 3.12

Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 2.98

Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. J Diabetes Complications (2005) 2.64

Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med (1996) 2.55

Articles by these authors

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28

Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78

Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care (2003) 29.49

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62

Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2008) 21.05

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14

Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30

Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35

Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24

Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med (2000) 10.05

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70

Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62

Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet (2010) 9.20

2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90

Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74

Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69

Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28

Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14

Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96

Effects of a physical activity intervention on measures of physical performance: Results of the lifestyle interventions and independence for Elders Pilot (LIFE-P) study. J Gerontol A Biol Sci Med Sci (2006) 6.61

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50

Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA (2012) 6.29

Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ (2010) 6.11

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03

Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med (2003) 5.87

Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46

American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care (2009) 5.41

Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26

Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation (2008) 5.15

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79

Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.78

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract (2011) 4.69

Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2005) 4.55

Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet (2010) 4.53